ORLEANS, ON, June 17, 2019 /CNW Telbec/ - Tetra
Bio-Pharma Inc. ("Tetra" or
the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global
leader in cannabinoid-based drug development and discovery, wishes
to announce a change in the previously set time for the
Corporation's Meeting, which was originally scheduled for
Thursday, June 20, 2019 at
2:00 p.m. (Eastern Daylight
Time).
Due to last minute impracticability reasons, the Meeting will
now be held at 10:00 a.m. (Eastern Daylight
Time). The date and the location remain unchanged, namely
Thursday, June 20, 2019 at the
offices of Stikeman Elliott LLP located at 1155, René-Lévesque
Blvd. West, 41st Floor, Montréal, Québec H3B 3V2. The
record date for determining shareholders entitled to receive notice
of and vote at the Meeting remains unchanged.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a
biopharmaceutical multifaced corporation with its primary focus in
cannabinoid-based drug discovery and development with a clinical
trial program aimed at bringing novel drugs and treatments to
patients and their healthcare providers. Tetra Bio-Pharma's
subsidiary, Tetra Natural Health, also focuses on the development
and commercialization of natural health and self-care products as
well as the sale of its hemp energy drinks.
For more information visit: www.tetrabiopharma.com and
www.tetranaturalhealth.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include, among other things, without limitation, the inability of
the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of CAUMZ
and its other drug candidates, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical
trials, the timing and outcomes of regulatory or intellectual
property decisions and other risks disclosed in the Company's
public disclosure record on file with the relevant securities
regulatory authorities. Although the Company has attempted to
identify important factors that could cause actual results or
events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities
legislation.
SOURCE Tetra Bio-Pharma Inc